The FDA would have to update drug testing rules within one year. The rules would replace many references to animal testing with broader language for nonclinical testing before human trials.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
FDA Modernization Act 3.0 is a House bill waiting for floor action. The latest recorded action: Placed on the Union Calendar, Calendar No. 614.
Latest action on H.R. 2821: Placed on the Union Calendar, Calendar No. 614.
Who this affects: This bill mainly affects drug companies, researchers, FDA staff, and groups that track animal use in research. Drug developers would see updated rules on what evidence FDA may accept before human trials. FDA would have to revise its rulebook quickly and may need to update more sections than the bill names. Patients and the public could see effects later, depending on how FDA applies these rules to drug safety reviews.
Why this matters: This bill matters because drug testing rules shape what evidence companies must show before testing drugs in people. Updating the wording could make FDA rules better match newer testing tools and recent law. It may also help companies understand when non-animal methods can support a drug application. The real effect will depend on FDA’s rule and how the agency judges safety evidence in each case.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
